MBXBF (Microbix Biosystems) Other Current Payables: $0.00 Mil (As of Mar. 2026)


MBXBF Microbix Biosystems Inc MBXBF
55 GF Score
Price $0.22
GF Value $0.18
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Microbix Biosystems Other Current Payables?

Microbix Biosystems MBXBF 55 Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus rates MBXBF with a GF Score™ of 55/100 and a GF Value™ of $0.18 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Microbix Biosystems's Other Current Payables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Microbix Biosystems Other Current Payables Related Terms

Microbix Biosystems Other Current Payables Historical Data

* Premium members only.

The historical data trend for Microbix Biosystems's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbix Biosystems Other Current Payables Chart

Microbix Biosystems Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Microbix Biosystems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MBXBF
55GF Score
Microbix Biosystems Inc MBXBF
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microbix Biosystems Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Microbix Biosystems (MBXBF) has a Other Current Payables of $0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Microbix Biosystems and its competitors.
Is Microbix Biosystems' Other Current Payables too high?
Microbix Biosystems' current Other Current Payables is $0.00 Mil. Overall, Microbix Biosystems has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Other Current Payables compare to VRTX and REGN?
Microbix Biosystems' Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.18, compared to a current price of $0.22 — trading 19.9% above its estimated fair value. The current Other Current Payables is $0.00 Mil. Microbix Biosystems' overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microbix Biosystems (MBXBF) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of $0.22 is trading 19.9% above its estimated GF Value™ of $0.18. GuruFocus considers Microbix Biosystems to be Modestly Overvalued.

Key valuation signals for MBXBF:

  • Other Current Payables: $0.00 Mil
  • GF Value™: $0.18 vs. price of $0.22 (19.9% above fair value)
  • GF Score™: 55/100 with 8 warning signs

No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microbix Biosystems Business Description

Other Exchanges MBX:Canada
Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
55GF Score

Get the complete analysis for MBXBF

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price
$0.18
GF Value